Literature DB >> 7495939

The relationship between the control of pH and healing and symptom relief in gastro-oesophageal reflux disease.

R H Hunt1.   

Abstract

Gastro-oesophageal reflux disease (GERD) is generally considered to be the result of a motility disorder which permits the abnormal and prolonged exposure of the lumen of the oesophagus to the acidic gastric contents. This view is supported by experimental data, intra-oesophageal pH measurement, and the dramatic results of symptom relief and healing seen with effective antisecretory treatment. Oesophageal mucosal injury is determined by the pH of the refluxate and duration of acid exposure. Most patients experience meal-stimulated reflux during the day and the more severe cases experience 24-h acid exposure. In contrast to the H2-receptor antagonists (H2RAs), the proton pump inhibitors (PPIs) are more effective at controlling meal-stimulated acid secretion when each is given in standard doses. Therefore, the degree and duration of acid suppression throughout 24 h is greater. Treatments which maintain intra-oesophageal pH > 4 for 96% or more of the 24 h normalize acid exposure and are associated with the highest healing rates. Peptic activity is minimized at or above pH 4. The time above pH 4 is significantly longer with the PPIs than with the H2RAs. Thus, the healing-time curves for GERD (grades II-IV) are shifted to the left for the PPIs which heal a significantly greater proportion of patients earlier than the H2RAs or sucralfate. Symptoms in GERD are related to the degree and duration of oesophageal acid exposure. Symptom relief is more rapid and complete with the PPIs than with the H2RAs or other treatments in standard doses.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7495939     DOI: 10.1111/j.1365-2036.1995.tb00777.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  31 in total

Review 1.  Gastro-oesophageal reflux disease and Helicobacter pylori: an intricate relation.

Authors:  D McNamara; C O'Morain
Journal:  Gut       Date:  1999-07       Impact factor: 23.059

Review 2.  Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.

Authors:  H D Langtry; M I Wilde
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

Review 3.  What is potent acid inhibition, and how can it be achieved?

Authors:  Xavier Calvet; Fernando Gomollón
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 4.  Healing of oesophagitis.

Authors:  L Rodrigo
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 5.  Treatment of gastroesophageal reflux disease.

Authors:  Michael Pettit
Journal:  Pharm World Sci       Date:  2005-12

Review 6.  Esomeprazole: in gastroesophageal reflux disease in children and adolescents.

Authors:  Jamie D Croxtall; Caroline M Perry; Gillian M Keating
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

7.  Gastroesophageal reflux disease: clinical features.

Authors:  Michael Pettit
Journal:  Pharm World Sci       Date:  2005-12

8.  Gastric acid-dependent diseases: a twentieth-century revolution.

Authors:  George Sachs; Jai Moo Shin; Keith Munson; David R Scott
Journal:  Dig Dis Sci       Date:  2014-07       Impact factor: 3.199

Review 9.  Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015.

Authors:  Katsuhiko Iwakiri; Yoshikazu Kinoshita; Yasuki Habu; Tadayuki Oshima; Noriaki Manabe; Yasuhiro Fujiwara; Akihito Nagahara; Osamu Kawamura; Ryuichi Iwakiri; Soji Ozawa; Kiyoshi Ashida; Shuichi Ohara; Hideyuki Kashiwagi; Kyoichi Adachi; Kazuhide Higuchi; Hiroto Miwa; Kazuma Fujimoto; Motoyasu Kusano; Yoshio Hoshihara; Tatsuyuki Kawano; Ken Haruma; Michio Hongo; Kentaro Sugano; Mamoru Watanabe; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2016-06-21       Impact factor: 7.527

Review 10.  Dexlansoprazole modified release: in erosive oesophagitis and non-erosive reflux disease.

Authors:  Jamie D Croxtall; Lesley J Scott
Journal:  Drugs       Date:  2010-08-20       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.